Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2022

View Archived Issues

Novel cdkl5-mutated zebrafish model of CDKL5 deficiency disorder

Insulin is tissue-specific, with link to weight complex

Purdue Research Foundation patents protein kinase inhibitors

Universite de Franche-Comte presents compounds targeting histamine H3 receptors

TCR-modified T cells targeting TdT show antileukemia promise in vivo

SCN5A tied to drug-induced cardiac arrythmia

PEGylated circularly permuted capsule depolymerase enzyme protects mice from anthrax infection

VelociT mouse model for analyzing T-cell function in human disease

Ono and Neurimmune expand drug discovery collaboration for neurodegenerative diseases

EZH2 as a promising therapeutic target for prostate cancer

MCC-1381, a pan-HDAC inhibitor with promising anticancer activity

ZIP8 found to correlate with severe rheumatoid arthritis

4basebio and eTheRNA collaborate to evaluate linear DNA for mRNA production

Avacta selects FAP-targeted proteasome inhibitor for preclinical development

SUW-133 diminishes HIV viral load in vivo

Researchers suggest ZEB2 targeting as an approach for atherosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...